Janux Therapeutics, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
Janux Therapeutics, Inc. (JANX) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $15.65 million as of 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2025-02-27
- 2024-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $15.65M.
- 2024-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $452.96M.
- 2024-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $263.96M.
- 2023-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $74.53M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2024-09-30 | $15.65M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $452.96M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $263.96M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $74.53M 10-K · filed 2025-02-27 |
| 2023-06-30 | $237.21M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $194.97M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $203.40M 10-K · filed 2024-03-08 |
| 2022-09-30 | $266.54M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |